These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
834 related articles for article (PubMed ID: 16773445)
1. Glutamate and schizophrenia: beyond the dopamine hypothesis. Coyle JT Cell Mol Neurobiol; 2006; 26(4-6):365-84. PubMed ID: 16773445 [TBL] [Abstract][Full Text] [Related]
2. Glutamatergic mechanisms in schizophrenia. Tsai G; Coyle JT Annu Rev Pharmacol Toxicol; 2002; 42():165-79. PubMed ID: 11807169 [TBL] [Abstract][Full Text] [Related]
3. Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia. Coyle JT; Tsai G; Goff D Ann N Y Acad Sci; 2003 Nov; 1003():318-27. PubMed ID: 14684455 [TBL] [Abstract][Full Text] [Related]
4. [Glutamate hypothesis of schizophrenia and targets for new antipsychotic drugs]. Hashimoto K; Iyo M Nihon Shinkei Seishin Yakurigaku Zasshi; 2002 Feb; 22(1):3-13. PubMed ID: 11917507 [TBL] [Abstract][Full Text] [Related]
5. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Goff DC; Coyle JT Am J Psychiatry; 2001 Sep; 158(9):1367-77. PubMed ID: 11532718 [TBL] [Abstract][Full Text] [Related]
6. Substance use disorders and Schizophrenia: a question of shared glutamatergic mechanisms. Coyle JT Neurotox Res; 2006 Dec; 10(3-4):221-33. PubMed ID: 17197372 [TBL] [Abstract][Full Text] [Related]
7. The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia. Coyle JT; Tsai G Psychopharmacology (Berl); 2004 Jun; 174(1):32-8. PubMed ID: 15205876 [TBL] [Abstract][Full Text] [Related]
8. Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia. Lindsley CW; Shipe WD; Wolkenberg SE; Theberge CR; Williams DL; Sur C; Kinney GG Curr Top Med Chem; 2006; 6(8):771-85. PubMed ID: 16719816 [TBL] [Abstract][Full Text] [Related]
9. Glutamate and dopamine dysregulation in schizophrenia--a synthesis and selective review. Stone JM; Morrison PD; Pilowsky LS J Psychopharmacol; 2007 Jun; 21(4):440-52. PubMed ID: 17259207 [TBL] [Abstract][Full Text] [Related]
10. Significance of dysfunctional glutamatergic transmission for the development of psychotic symptoms. Pietraszek M Pol J Pharmacol; 2003; 55(2):133-54. PubMed ID: 12926541 [TBL] [Abstract][Full Text] [Related]
11. Glutamatergic synaptic dysregulation in schizophrenia: therapeutic implications. Coyle JT; Basu A; Benneyworth M; Balu D; Konopaske G Handb Exp Pharmacol; 2012; (213):267-95. PubMed ID: 23027419 [TBL] [Abstract][Full Text] [Related]
12. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions. Javitt DC Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858 [TBL] [Abstract][Full Text] [Related]
13. The NMDA receptor 'glycine modulatory site' in schizophrenia: D-serine, glycine, and beyond. Balu DT; Coyle JT Curr Opin Pharmacol; 2015 Feb; 20():109-15. PubMed ID: 25540902 [TBL] [Abstract][Full Text] [Related]
14. [Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine]. Mechri A; Saoud M; Khiari G; d'Amato T; Dalery J; Gaha L Encephale; 2001; 27(1):53-9. PubMed ID: 11294039 [TBL] [Abstract][Full Text] [Related]
15. The GABA-glutamate connection in schizophrenia: which is the proximate cause? Coyle JT Biochem Pharmacol; 2004 Oct; 68(8):1507-14. PubMed ID: 15451393 [TBL] [Abstract][Full Text] [Related]
16. Mechanism of action of antipsychotic drugs: from dopamine D(2) receptor antagonism to glutamate NMDA facilitation. Laruelle M; Frankle WG; Narendran R; Kegeles LS; Abi-Dargham A Clin Ther; 2005; 27 Suppl A():S16-24. PubMed ID: 16198197 [TBL] [Abstract][Full Text] [Related]
17. [Role of astrocytes in alterations of glutamatergic neurotransmission in schizophrenia]. Kolomeets NS Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(1):110-117. PubMed ID: 25945378 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of glycine transporter 1: The yellow brick road to new schizophrenia therapy? Singer P; Dubroqua S; Yee BK Curr Pharm Des; 2015; 21(26):3771-87. PubMed ID: 26205290 [TBL] [Abstract][Full Text] [Related]
19. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Jentsch JD; Roth RH Neuropsychopharmacology; 1999 Mar; 20(3):201-25. PubMed ID: 10063482 [TBL] [Abstract][Full Text] [Related]
20. Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment. Laruelle M; Kegeles LS; Abi-Dargham A Ann N Y Acad Sci; 2003 Nov; 1003():138-58. PubMed ID: 14684442 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]